Clinical Trial Details


Research Study Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine


The purpose of this clinical trial is to determine whether an investigational treatment, when added to either rituximab or cyclophosphamide, can improve your vasculitis disease activity, kidney function, and/or quality of life.

To Learn more

CW ID: 226605
Date Last Changed: September 12, 2017

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Facility Type


You may qualify for this Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Study study, if:
  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
  • Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with cyclophosphamide or rituximab is neededa


ANITA FARHI, RN, Research Nurse
NYU Winthrop Hospital, Clinical Research Center
101 Mineola Blvd. 3-002
Mineola, NY 11501
Phone: 516-663-9582
Fax: 516-663-9587

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.